<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918654</url>
  </required_header>
  <id_info>
    <org_study_id>RND3_MED-EL_CRD_2020_03</org_study_id>
    <nct_id>NCT04918654</nct_id>
  </id_info>
  <brief_title>Automatic Sound Management 3.0 in a Single-unit Audio Processor</brief_title>
  <acronym>RND3</acronym>
  <official_title>Automatic Sound Management 3.0 in a Single-unit Audio Processor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MED-EL Elektromedizinische Geräte GesmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MED-EL Elektromedizinische Geräte GesmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cochlear implants are routine treatment for people with severe hearing loss. This study tests&#xD;
      the RONDO 3, MED-EL's newest single-unit audio processor which comes with new features&#xD;
      (Beamformer, Wind-Noise reduction, Ambient noise reduction, Transient noise reduction,&#xD;
      Adaptive intelligence).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MED-EL Cochlear Implants (CI) provide auditory sensations via electrical stimulation of the&#xD;
      auditory pathways for severely to profoundly hearing-impaired individuals who obtain little&#xD;
      or no benefit from acoustic amplification in the best aided condition. Front-end processing&#xD;
      of acoustic signals picked up by the audio processor is routinely applied to provide optimal&#xD;
      hearing performance under varying listening conditions. Automatic Sound Management (ASM) was&#xD;
      introduced by MED-EL with the TEMPO+ audio processor and provided advanced compression and&#xD;
      automatic gain management. With the SONNET audio processor, MED-EL introduced ASM 2.0, which&#xD;
      added wind noise reduction and microphone directionality to the front-end processing. With&#xD;
      the SONNET 2 audio processor, ASM 3.0 was implemented and the features ambient noise&#xD;
      reduction, transient noise reduction and an adaptive intelligence (AI) were added. The RONDO&#xD;
      3 implements now ASM 3.0.&#xD;
&#xD;
      This study investigates the impact of ASM 3.0 as implemented in the RONDO 3 on CI users'&#xD;
      speech performance and their subjective quality of hearing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Speech in noise</measure>
    <time_frame>Baseline</time_frame>
    <description>Oldenburg Sentence Test in noise (S0 N±90 N180)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Hearing</measure>
    <time_frame>Baseline</time_frame>
    <description>Hearing Implant Sound Quality Index (HISQUI). Min score: 16, Max score 133. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Satisfaction</measure>
    <time_frame>Baseline</time_frame>
    <description>Audio Processor Satisfaction Questionnaire. Min score: 0, Max score 10. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User Satisfaction</measure>
    <time_frame>Baseline</time_frame>
    <description>Product-specific questionnaire. The questionnaire is not reporting a single score on a scale (min/max score not applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech in noise</measure>
    <time_frame>Baseline</time_frame>
    <description>Oldenburg Sentence Test in noise (S0 N±90 N180)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech in noise</measure>
    <time_frame>Baseline</time_frame>
    <description>Oldenburg Sentence Test in noise (S0 N0)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cochlear Implants</condition>
  <arm_group>
    <arm_group_label>Study Subjects</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Post-lingually deafened adult cochlear implant users with a MED-EL device.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A minimum of 18 years old&#xD;
&#xD;
          -  Experienced user of a RONDO 3 (≥ 6 months) for the ear to be tested&#xD;
&#xD;
          -  Post-lingual onset of bilateral severe to profound sensory-neural hearing loss&#xD;
&#xD;
          -  A minimum of 40% speech recognition in the Freiburg Monosyllables Test in quiet at 65&#xD;
             dB SPL for the ear to be tested (at the last time tested in clinical routine)&#xD;
&#xD;
          -  Signed and dated Informed Consent Form (ICF) before the start of any study-specific&#xD;
             procedure.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Lack of compliance with any inclusion criteria&#xD;
&#xD;
          -  CI user with contralateral hearing equal to or better than 60 dB (pure-tone average&#xD;
             over the following frequencies: 250, 500, 1000, and 2000 Hz)&#xD;
&#xD;
          -  Implanted with C40X, or C40C on the ear to be tested&#xD;
&#xD;
          -  Implanted with an Auditory Brainstem Implant (ABI) or split electrode array&#xD;
&#xD;
          -  Known allergic reactions to components of the investigational medical device (RONDO 3)&#xD;
             or the SONNET 2&#xD;
&#xD;
          -  Anything that, in the opinion of the Investigator, would (a) place the subject at&#xD;
             increased risk, (b) preclude the subject's full compliance with or completion of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>MHH - Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Büchner, Prof. Dr.</last_name>
      <phone>+49 511 532</phone>
      <phone_ext>6837</phone_ext>
      <email>buechner.andreas@mh-hannover.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

